Total Payments
$2.3M
2024 Payments
$583,722
Companies
53
Transactions
2,474
Medicare Patients
8,472
Medicare Billing
$749,007
Payment Breakdown by Category
Other$1.2M (53.1%)
Consulting$564,895 (24.3%)
Research$314,663 (13.6%)
Travel$154,001 (6.6%)
Food & Beverage$50,286 (2.2%)
Education$5,169 (0.2%)
Gifts$11.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $965,268 | 351 | 41.6% |
| Consulting Fee | $564,895 | 156 | 24.3% |
| Unspecified | $314,663 | 111 | 13.6% |
| Travel and Lodging | $154,001 | 431 | 6.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $75,600 | 25 | 3.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $73,500 | 21 | 3.2% |
| Grant | $68,750 | 4 | 3.0% |
| Food and Beverage | $50,286 | 1,311 | 2.2% |
| Honoraria | $48,885 | 22 | 2.1% |
| Education | $5,169 | 41 | 0.2% |
| Gift | $11.00 | 1 | 0.0% |
Payments by Type
General
$2.0M
2,363 transactions
Research
$314,663
111 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC | $298,718 | 327 | $0 (2024) |
| Galderma Laboratories, L.P. | $271,692 | 366 | $0 (2024) |
| PFIZER INC. | $177,191 | 184 | $0 (2024) |
| Allergan, Inc. | $174,389 | 128 | $0 (2022) |
| Almirall LLC | $162,784 | 107 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $161,820 | 108 | $0 (2024) |
| UCB, Inc. | $126,211 | 118 | $0 (2024) |
| Bausch Health US, LLC | $106,172 | 6 | $0 (2019) |
| Incyte Corporation | $99,483 | 98 | $0 (2024) |
| ABBVIE INC. | $98,742 | 171 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $583,722 | 495 | UCB, Inc. ($110,981) |
| 2023 | $515,869 | 535 | Galderma Laboratories, L.P. ($90,256) |
| 2022 | $324,436 | 366 | PFIZER INC. ($54,221) |
| 2021 | $163,023 | 209 | Ortho Dermatologics, a division of Bausch Health US, LLC ($56,723) |
| 2020 | $145,949 | 159 | Galderma Laboratories, L.P. ($45,100) |
| 2019 | $323,523 | 393 | Ortho Dermatologics, a division of Bausch Health US, LLC ($90,274) |
| 2018 | $160,268 | 175 | Bausch Health US, LLC ($77,022) |
| 2017 | $104,238 | 142 | Allergan Inc. ($33,433) |
All Payment Transactions
2,474 individual payment records from CMS Open Payments — Page 1 of 99
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug), DUOBRII | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,075.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,075.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $20.60 | General |
| Category: Immunology | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,130.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $64.45 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $2.10 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,750.00 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $821.47 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $423.12 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $357.91 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $173.34 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $173.34 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $128.22 | General |
| 12/10/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,880.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $13.37 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $106,172 | 6 |
| CFW-3A | Nielsen BioSciences, Inc. | $64,078 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $34,379 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $20,632 | 4 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $19,310 | 2 |
| CFW-2D | Nielsen BioSciences, Inc. | $18,076 | 2 |
| GBR830-204 | Ichnos Sciences Inc. | $16,456 | 11 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly Export S.A. Puerto Rico Branch | $11,238 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $3,690 | 1 |
| A PHASE 3 MULTICENTER, DOUBLE-BLIND STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN ADULT PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $3,671 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $3,500 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $3,386 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $3,079 | 54 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,756 | 3 |
| ISB830-204 | Ichnos Sciences Inc. | $1,432 | 1 |
| MMP Scale Validation Study | ABBVIE INC. | $1,307 | 9 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS | Eli Lilly and Company | $785.60 | 2 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $704.34 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis. | Allergan Inc. | $686.22 | 5 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $221.80 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,822 | 3,825 | $442,588 | $148,046 |
| 2022 | 24 | 1,820 | 3,773 | $628,347 | $178,759 |
| 2021 | 22 | 2,282 | 4,321 | $778,796 | $177,544 |
| 2020 | 25 | 2,548 | 5,291 | $1.1M | $244,659 |
Total Patients
8,472
Total Services
17,210
Medicare Billing
$749,007
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 408 | 562 | $103,558 | $35,978 | 34.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 176 | 220 | $52,601 | $17,804 | 33.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 314 | 425 | $59,379 | $16,570 | 27.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 161 | 198 | $42,262 | $12,835 | 30.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 66 | 78 | $27,529 | $9,440 | 34.3% |
| 77401 | Superficial and/or low voltage radiation treatment delivery | Office | 2023 | 15 | 259 | $22,676 | $8,874 | 39.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 247 | 1,542 | $21,752 | $8,158 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 84 | 98 | $25,476 | $8,154 | 32.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 80 | 123 | $14,259 | $4,905 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 50 | 50 | $11,390 | $3,937 | 34.6% |
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Office | 2023 | 14 | 17 | $9,715 | $3,814 | 39.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 15 | 15 | $9,542 | $3,563 | 37.3% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 18 | 22 | $8,181 | $3,048 | 37.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 46 | 68 | $7,168 | $2,813 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $4,057 | $1,575 | 38.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 14 | $3,698 | $1,377 | 37.2% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 13 | 13 | $6,620 | $1,300 | 19.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 23 | 34 | $4,038 | $1,141 | 28.3% |
| 69100 | Biopsy of ear | Office | 2023 | 16 | 17 | $3,426 | $989.09 | 28.9% |
| 10040 | Acne surgery | Office | 2023 | 11 | 11 | $2,680 | $949.52 | 35.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 17 | 17 | $2,518 | $795.02 | 31.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 22 | 30 | $63.60 | $24.45 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 426 | 565 | $114,830 | $34,021 | 29.6% |
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Office | 2022 | 15 | 138 | $117,399 | $32,177 | 27.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 212 | 241 | $67,829 | $19,638 | 29.0% |
About Dr. Edward Lain, M.D
Dr. Edward Lain, M.D is a Dermatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124079306.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Lain, M.D has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $583,722 received in 2024. These payments were reported across 2,474 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($965,268).
As a Medicare-enrolled provider, Lain has provided services to 8,472 Medicare beneficiaries, totaling 17,210 services with total Medicare billing of $749,007. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Austin, TX
- Active Since 05/13/2006
- Last Updated 06/09/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1124079306
Products in Payments
- AKLIEF (Drug) $154,603
- Sotyktu (Drug) $149,465
- SILIQ (Drug) $139,131
- Bimzelx (Biological) $116,393
- Klisyri (Drug) $104,084
- CIBINQO (Drug) $101,493
- Candin (Biological) $82,153
- OPZELURA (Drug) $82,051
- DUOBRII (Drug) $71,473
- DUPIXENT (Biological) $61,304
- VTAMA (Drug) $53,398
- QBREXZA (Drug) $43,536
- BOTOX (Biological) $40,040
- EUCRISA (Drug) $37,956
- OLUMIANT (Drug) $37,453
- LITFULO (Drug) $33,048
- ADBRY (Biological) $31,563
- Zoryve (Drug) $27,956
- BOTOX COSMETIC (Biological) $25,381
- Cabtreo (Drug) $23,013
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Austin
Daniel Carrasco, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Dale Schaefer, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Janet Dubois, M.d, M.D
Dermatology — Payments: $1.1M
Dermatology $1.1M
Ms. Heidi Prather, M.d, M.D
Dermatology — Payments: $530,857
Dermatology $530,857
Daniel Friedmann, M.d, M.D
Dermatology — Payments: $231,608
Dermatology $231,608
Dr. Jennifer Gordon, Md, MD
Dermatology — Payments: $161,696
Dermatology $161,696